Retinal vein occlusion: Anti-VEGF treatments;Occlusions veineuses rétiniennes : traitements anti-VEGF

Journal Francais d'Ophtalmologie

Volumn 32, Issue 9, 2009, Pages 679-686

  Nghiem Buffet, S ^a,b   Cohen, S Y ^a  

^a Centre Ophtalmologique d'Imagerie et de Laser   (France)

^b AVICENNE HOSPITAL   (France)

Author keywords

Bevacizumab; Macular edema; Ranibizumab; Retinal vein occlusion; Vascular Endothelial Growth Factor

Indexed keywords

EID: 73449140073     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jfo.2009.10.002     Document Type: Review

References (36)

1. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch retinal occlusion. Am J Ophthalmol 1984; 98:271-282
2. The Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central retinal vein occlusion: the Central Vein Occlusion Sudy Group M Report. Ophthalmology 1995; 102:1425-1433
3. Gregori NZ, Rosenfeld PJ, Puliafito CA, Flynn Jr HW, Lee JE, Mavrofrides EC, et al.. One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion. Retina 2006;26:889-895
4. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al.. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487
5. Boyd SR, Zachary I, Chakravarthy, Allen GJ, Wisdom GB, Cree IA, et al.. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol 2002;120:1644-1650
6. Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, et al.. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmology 2005;140:256-261
7. Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 1998;105:412-416
8. Tolentino MJ, McLeod DS, Taomoto M, Otsuji T, Adamis AP, Lutty GA. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 2002;133:373-385
9. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336-339
10. Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, et al.. Intravitreal Bevacizumab (avastin) treatment of macular edema in central retinal vein occlusion: a shortterm study. Retina 2006;26:279-284
11. Stahl A, Agostini H, Hansen LL, Feltgen N. Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefes Arch Clin Exp Ophthalmol 2007;245:1429-1436
12. Costa RA, Jorge R, Calluci D, Melo Jr LA, Cardillo JA, Scott IU. Intravitreal Bevacizumab (Avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 2007;27:141-149
13. Priglinger SG, Wolf AH, Kreutzer TC, Kook D, Hofer A, Strauss RW, et al.. Intravitreal Bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina 2007;27:1004-1012
14. Pournaras JA, Nguyen C, Vaudaux JD, Konstantinidis L, Ambresin A, Wolfensberger T. Treatment of central retinal vein occlusion-related macular edema with intravitreal bevacizumab (Avastin): preliminary results. Klin Monatsbl Augenheilkd 2008;225:397-400.
15. Hsu J, Kaiser RS, Sivalingam A, Abraham P, Fineman MS, Saluel MA, et al.. Intravitreal Bevacizumab (avastin) in central retinal vein occlusion. Retina 2007;27:1013-1019
16. Matsumoto Y, Freund KB, Peiretti E, Cooney MJ, Ferrara DC, Yannuzzi LA. Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. Retina 2007;27:426-431
17. Badala F. The treatment of branch retinal vein occlusion with bevacizumab. Curr Opin Ophthalmol 2008;192:234-238
18. Kreutzer TC, Alge CS, Wolf AH, Kook D, Burger J, Strauss R, et al.. Intravitreal bevacizumab for the treatment of macular edema secondary to branch retinal vein occlusion. Br J Ophthalmol 2008;92:351-355
19. Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL, Intravitreal Bevacizumab. (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 2007;27:419-425
20. Gregori NZ, Gaitan J, Rosenfeld PJ, Puliafito CA, FeuerW, Flynn Jr HW, et al.. Long-term safety anf efficacy of intravitreal bevacizumab (avastin) for the managment of central retinal vein occlusion. Retina 2008;28:1325-1337
21. Ferrara DC, Koizumi H, Spaide RF. Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol 2007;144:864-871 (Pubitemid 350122344)
22. Alkuraya HS, Al-Kharashi AS, Alharthi E, Chaudhry IA. Acute endophthalmitis caused by Staphylococcus lugdunesis after intravitreal bevacizumab (Avastin) injection. Int Ophthalmol 2009;29:411-413
23. Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK, et al.. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 2007;143:601-606
24. Moschos MM, Moschos M. Intraocular bevacizumab for macular edema due to CRVO. A multifocal-ERG and OCT study. Doc Ophthalmol 2008;116:147-152
25. Ekdawi NS, Bakri SJ. Intravitreal triamcinolone and bevacizumab combination therapy for macular edema due to central retinal vein occlusion refractory to either treatment alone. Eye 2007;21:1128-1130
26. Schaal KB, Höh AE, Scheuerle A, Schütt F, Schütt F, Dithmar S. Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion. Ophthalmologe 2007;104:285-289
27. Abegg M, Tappeiner C, Wolf-Schnurrbusch U, Barthelmes D, Wolf S, Fleischhauer J. Treatment of branch retinal vein occlusion induced macular edema with bevacizumab. BMC Ophthalmol 2008;29(8):18.
28. Wu L, Arevalo JF, Roca JA, Maia M, Berrocal MH, Rodriguez FJ, et al.. Pan-American Collaborative Retina Study Group (PACORES). Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina 2008;28:212-219
29. Pieramici DJ, Rabena M, Castellarin, Nasir M, See R, Norton T, et al.. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Ophthalmology 2008;115:47-54.
30. Spaide RF, Chang LK, Klancnik JM, Yannuzzi LA, Sorenson J, Slakter JS, et al.. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 2009;147: 298-306.
31. Spandau UH, Ihloff AK, Jonas JB. Intravitreal bevacizumab treatment of macular oedema due to central retinal vein occlusion. Acta Ophthalmol Scand 2006;84:555-556
32. Spandau UH, Wickenhäuser A, Rensch F, Jonas JB. Intravitreal bevacizumab for branch retinal vein occlusion. Acta Ophthalmol Scand 2007;85:118-119
33. Gündüz K, Bakri SJ. Intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion. Eye 2008;22:1168-1171
34. Byeon SH, Kwon YA, Oh HS, Kim M, Kwon OW. Short-term results of intravitreal bevacizumab for macular edema with retinal vein obstruction and diabetic macular edema. J Ocul Pharmacol Ther 2007;23:387-394
35. Shetty R, Pai SA, Vincent A, Shetty N, Narayana KM, Sinha B, et al.. Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema. Doc Ophthalmol 2008;116:129-135
36. Kriechbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenauer W, et al.. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 2008;92:518-522